Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 5 vs ENZALUTAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Androgen receptor inhibitor; binds to the androgen receptor and inhibits androgen receptor nuclear translocation, DNA binding, and coactivator recruitment.
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
Treatment of metastatic castration-resistant prostate cancer,Treatment of metastatic castration-sensitive prostate cancer
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
160 mg orally once daily
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Terminal elimination half-life is approximately 5.8 days (range 2.8–10.2 days) after steady state; supports once-daily dosing.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Primarily metabolized by CYP2C8 and CYP3A4; forms active metabolite N-desmethyl enzalutamide
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Primarily hepatic metabolism; ~70% of dose excreted in feces (as unchanged drug and metabolites), ~1% in urine as unchanged drug. Biliary excretion is a major route.
98% bound to sex hormone-binding globulin (SHBG) and albumin.
97–98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Approximately 110 L (1.1 L/kg for a 70 kg patient); indicates extensive extravascular distribution.
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
Oral bioavailability is not published; absorption is at least moderate based on systemic exposure. Food does not significantly affect absorption.
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment (e GFR 30-89 m L/min). Insufficient data for severe renal impairment (e GFR <30 m L/min) or end-stage renal disease.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
No dose adjustment for mild hepatic impairment (Child-Pugh A). For moderate (Child-Pugh B): reduce dose to 80 mg once daily. Not recommended for severe (Child-Pugh C).
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
Not approved for use in pediatric patients; safety and efficacy not established.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
No specific dose adjustment required; elderly patients may be more susceptible to adverse effects such as falls, fractures, and hypertension. Monitor closely.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
None
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Seizure risk,Posterior reversible encephalopathy syndrome (PRES),Hypersensitivity reactions including angioedema,Increased risk of falls and fractures,Embryo-fetal toxicity
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
Pregnancy,Concomitant use with strong CYP2C8 inhibitors or inducers,Concomitant use with strong CYP3A4 inducers
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
No significant food interactions. Avoid grapefruit juice as it may increase enzalutamide levels (minor interaction). Take with or without food.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Enzalutamide is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibitor), there is a high risk of fetal harm, particularly male pseudohermaphroditism and impaired reproductive development. Use should be avoided in all trimesters. Women of childbearing potential must use effective contraception during treatment and for 1 month after the last dose.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
No human data available. Enzalutamide and its active metabolite are likely excreted into human milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment and for 1 month after the last dose. M/P ratio is unknown.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
Enzalutamide is contraindicated in pregnancy; therefore, no dose adjustments are recommended. If exposure occurs, discontinue the drug and manage according to clinical judgment. Pregnancy induces metabolic changes (e.g., increased hepatic clearance, plasma volume expansion) that could theoretically reduce exposure, but no data exist to support a specific dose adjustment.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Monitor for seizure risk, especially in patients with predisposing factors; enzalutamide may cause hypertension, so check blood pressure regularly; it significantly induces CYP3A4, reducing efficacy of oral contraceptives and other CYP3A4 substrates; use with caution in patients with history of cardiovascular disease; discontinue 5 half-lives before starting another antiandrogen.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
Take the capsules whole, with or without food, at the same time each day.,Do not crush, chew, or open the capsules.,Report any signs of seizure (e.g., convulsions, loss of consciousness) to your doctor immediately.,Enzalutamide may raise your blood pressure; have it checked regularly.,Use effective non-hormonal contraception during treatment and for 3 months after stopping; hormonal contraceptives may not work.,This drug may cause fatigue, falls, and fractures; avoid activities requiring alertness until you know how it affects you.,Notify your doctor if you experience chest pain, shortness of breath, or leg swelling.,Seek immediate medical attention for symptoms of posterior reversible encephalopathy syndrome (PRES): headache, confusion, visual disturbances.
No interactions on record
"Rifaximin is a non-systemic antibiotic with minimal oral absorption (<0.4%), thus is not expected to significantly affect systemic drug metabolism. However, in vitro studies suggest rifaximin can induce the expression of CYP3A4, the major enzyme responsible for the metabolism of enzalutamide. Although clinical data are limited, coadministration could theoretically decrease enzalutamide exposure, reducing its efficacy in treating prostate cancer; conversely, the baseline description suggests an increase, but evidence is conflicting."
"Enzalutamide, a potent CYP3A4 inducer, significantly reduces the exposure of diclofenac, a CYP2C9 substrate, by increasing its hepatic metabolism. This interaction can lead to subtherapeutic diclofenac concentrations, thereby diminishing its analgesic and anti-inflammatory efficacy. Clinically, patients may experience inadequate pain control or exacerbation of inflammatory conditions, such as arthritis, when these agents are coadministered."
"Enzalutamide, a potent androgen receptor inhibitor, significantly induces CYP3A4 and other drug-metabolizing enzymes. Dienogest, a progestin used in endometriosis and contraception, is primarily metabolized by CYP3A4. Coadministration leads to markedly reduced dienogest plasma concentrations, potentially diminishing its therapeutic efficacy in managing endometriosis symptoms or contraceptive effectiveness."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 5 vs ENZALUTAMIDE, answered by our medical review team.
ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. ENZALUTAMIDE is a Androgen Receptor Inhibitor that works by Androgen receptor inhibitor; binds to the androgen receptor and inhibits androgen receptor nuclear translocation, DNA binding, and coactivator recruitment.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 5 and ENZALUTAMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. The standard adult dose of ENZALUTAMIDE is: 160 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 5 and ENZALUTAMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. ENZALUTAMIDE is classified as Category D/X. Enzalutamide is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibitor), there is a high risk of fetal harm, particularly male pseudohermaphrod. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.